Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 13;10(2):275.
doi: 10.3390/jcm10020275.

Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study

Nicola Cosentino  1 , Jeness Campodonico  1 , Marco Moltrasio  1 , Claudia Lucci  1 , Valentina Milazzo  1 , Mara Rubino  1 , Monica De Metrio  1 , Ivana Marana  1 , Marco Grazi  1 , Alice Bonomi  1 , Fabrizio Veglia  1 , Gianfranco Lauri  1 , Antonio L Bartorelli  1   2 , Giancarlo Marenzi  1
Affiliations

Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study

Nicola Cosentino et al. J Clin Med. .

Abstract

Background: Mitochondrial biomarkers have been investigated in different critical settings, including ST-elevation myocardial infarction (STEMI). Whether they provide prognostic information in STEMI, complementary to troponins, has not been fully elucidated. We prospectively explored the in-hospital and long-term prognostic implications of cytochrome c and cell-free mitochondrial DNA (mtDNA) in STEMI patients undergoing primary percutaneous coronary intervention.

Methods: We measured cytochrome c and mtDNA at admission in 466 patients. Patients were grouped according to mitochondrial biomarkers detection: group 1 (-/-; no biomarker detected; n = 28); group 2 (-/+; only one biomarker detected; n = 283); group 3 (+/+; both biomarkers detected; n = 155). A composite of in-hospital mortality, cardiogenic shock, and acute pulmonary edema was the primary endpoint. Four-year all-cause mortality was the secondary endpoint.

Results: Progressively lower left ventricular ejection fractions (52 ± 8%, 49 ± 8%, 47 ± 9%; p = 0.006) and higher troponin I peaks (54 ± 44, 73 ± 66, 106 ± 81 ng/mL; p = 0.001) were found across the groups. An increase in primary (4%, 14%, 19%; p = 0.03) and secondary (10%, 15%, 23%; p = 0.02) endpoint rate was observed going from group 1 to group 3. The adjusted odds ratio increment of the primary endpoint from one group to the next was 1.65 (95% CI 1.04-2.61; p = 0.03), while the adjusted hazard ratio increment of the secondary endpoint was 1.55 (95% CI 1.12-2.52; p = 0.03). The addition of study group allocation to admission troponin I reclassified 12% and 22% of patients for the primary and secondary endpoint, respectively.

Conclusions: Detection of mitochondrial biomarkers is common in STEMI and seems to be associated with in-hospital and long-term outcome independently of troponin.

Keywords: ST-elevation myocardial infarction; cell-free mitochondrial DNA; cytochrome c; prognosis; troponin I.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results

Figures

Figure 1
Figure 1
Left ventricular ejection fraction (LVEF; upper panel) and high-sensitivity troponin I (hs-TnI; lower panel) peak values stratified according to cytochrome c and/or mtDNA detection at hospital admission (group 1 (−/−; none mitochondrial biomarker detected) vs. group 2 (−/+; only one of the two biomarkers detected) vs. group 3 (+/+; both biomarkers detected)). p value for trend was obtained by one-way analysis of covariance (ANCOVA).
Figure 2
Figure 2
Rate of the primary endpoint (in-hospital mortality, acute pulmonary edema, and cardiogenic shock). Group 1 (−/−; no mitochondrial biomarker detected) vs. group 2 (−/+; only one of the two biomarkers detected) vs. group 3 (+/+; both biomarkers detected)). p value for trend was obtained by Mantel–Haenszel chi-square.
Figure 3
Figure 3
Kaplan–Meier curve analysis for long-term all-cause mortality stratified according to cytochrome c and/or mtDNA detection at hospital admission (group 1 (−/−; no mitochondrial biomarker detected) vs. group 2 (−/+; only one of the two biomarkers detected) vs. group 3 (+/+; both biomarkers detected)). p value was obtained by log-rank test.
See this image and copyright information in PMC

References

    1. Keeley E.C., Hillis L.D. Primary PCI for Myocardial Infarction with ST-Segment Elevation. N. Engl. J. Med. 2007;356:47–54. doi: 10.1056/NEJMct063503. - DOI - PubMed
    1. Niccoli G., Kharbanda R.K., Crea F., Banning A.P. No-reflow: Again prevention is better than treatment. Eur. Heart J. 2010;31:2449–2455. doi: 10.1093/eurheartj/ehq299. - DOI - PubMed
    1. Bernardi P., Di Lisa F., Fogolari F., Lippe G. From ATP to PTP and back: A dual function for the mitochondrial ATP synthase. Circ. Res. 2015;116:1850–1862. doi: 10.1161/CIRCRESAHA.115.306557. - DOI - PMC - PubMed
    1. Chen Q., Camara A.K., Stowe D.F., Hoppel C.L., Lesnefsky E.J. Modulation of electron transport protects cardiac mitochondria and decreases myo-cardial injury during ischemia and reperfusion. Am. J. Physiol. Cell Physiol. 2007;292:C137–C147. doi: 10.1152/ajpcell.00270.2006. - DOI - PubMed
    1. Kutala V.K., Khan M., Angelos M.G., Kuppusamy P. Role of Oxygen in Postischemic Myocardial Injury. Antioxid. Redox Signal. 2007;9:1193–1206. doi: 10.1089/ars.2007.1636. - DOI - PubMed